NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
Clinical Trials
12 trialsNCT06157996 2025-05-30
Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT03469557 2024-10-23
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
BeiGene
Phase 2 Completed
NCT06451211 2024-06-11
Neo-ICEBOAT
Sun Yat-sen University
Phase 2 Recruiting
NCT04799548 2024-05-23
A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma
Shanghai Zhongshan Hospital
Phase 2 Recruiting
NCT06374901 2024-04-19
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
Zhejiang Cancer Hospital
Phase 2 Not yet recruiting
NCT06238167 2024-02-02
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05751265 2023-06-22
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT05687357 2023-04-19
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05536102 2023-03-09
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Recruiting
NCT04777162 2021-03-04
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
Peking University
Phase 2 Unknown